Loading stock data…
EHC
$107.48+7.48 (+7.48%)
Market ClosedLast close May 1
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Encompass Health Corporation in the Healthcare sector is trading at $107.48. The stock is currently 16% below its 52-week high of $127.99, remaining 3.3% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why EHC maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$107.48
Potential Upside
21.5%
Whystock Fair Value$130.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$141.82+31.9%
Range$130.00 – $153.00
Fundamentals
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.35
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Strong income play. Yield provides a meaningful total return floor.
74.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.44%
Volume
Today's trading volume
1.71M
Recent News
Encompass Health Q1 Earnings Call Highlights
Encompass Health (NYSE:EHC) reported first-quarter 2026 results that management said reflect strong underlying demand for inpatient rehabilitation facility (IRF) services, improving staffing trends, and continued investment in new capacity. The company also raised its full-year 2026 guidance followi
Encompass Health (EHC) Q1 2026 Earnings Transcript
With that, I'll turn the call over to President and Chief Executive Officer, Mark Tarr. Mark Tarr: Thank you, Mark, and good morning, everyone. Based primarily on our Q1 results, we are raising our guidance for 2026.
ITGR Stock Up Despite Q1 Earnings Missing Estimates, Revenues Rise Y/Y
Integer's shares jump despite a Q1 EPS miss and margin pressure, as revenues rise slightly Y/Y and beat estimates on strength across key product lines.
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
DXCM stock jumps on Q1 beat as revenues rise 15% and margins expand, with strong CGM demand and raised profitability outlook boosting momentum.
Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings
IDXX heads into Q1 earnings with strong growth forecasts, steady estimate beats, and momentum in diagnostics and recurring revenue streams.